Plotkin's Vaccines, 8th Edition
| ISBN: | 9780323790581 |
| Συγγραφέας: | Stanley A. Plotkin |
| Συγγραφείς: | Kathryn M. Edwards, Paul A. Offit |
| Ημ/νία έκδοσης: | 05/2023 |
| Μορφή: | Έντυπο |
| Αριθμός έκδοσης: | 8η έκδοση |
| Διαστάσεις: | 28x22 |
| Σελίδες: | 575 |
347,00€11% έκπτωση
309,00€ (συμπ. ΦΠΑ 6%)
11-14 ημέρες Υπό την προϋπόθεση ύπαρξης αποθέματος στον εκδότη
From the latest vaccination evidence, recommendations, and protocols . . . to new vaccine development and the use of vaccines in reducing disease, Plotkin’s Vaccines, 8th Edition, covers every aspect of vaccination. Now completely revised and updated from cover to cover, this award-winning text continues to provide reliable information from global authorities, offering a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin’s Vaccines is a must-have reference for current, authoritative information in this fast-moving field.
Key Features
- Contains all-new chapters on COVID-19, vaccine hesitancy, and non-specific effects of vaccines, as well as significantly revised content on new vaccine technologies such as mRNA vaccines, emerging vaccines, and technologies to improve immunization.
- Presents exciting new data on evolution of adjuvants across the centuries, dengue vaccines, human papillomavirus vaccines, respiratory syncytial virus vaccines, tuberculosis vaccines, and zoster vaccines.
- Provides up-to-date, authoritative information on vaccine production, available preparations, efficacy and safety, and recommendations for vaccine use, with rationales and data on the impact of vaccination programs on morbidity and mortality.
- Provides complete coverage of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
- Keeps you up to date with information on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
- Covers vaccine-preventable diseases, vaccine science, and licensed vaccine products, as well as product technologies and global regulatory and public health issues.
- Analyzes the cost-benefit and cost-effectiveness of different vaccine options.
- Helps you clearly visualize concepts and objective data through an abundance of tables and figures.
- Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
Author Information
By Walter A. Orenstein, MD, DSc (HON), Professor of Medicine and Pediatrics, and Global Health, Emory University; Associate Director, Emory Vaccine Center, Atlanta GA; Bill & Melinda Gates Foundation, Seattle, WA; Former Director, National Immunization Program, Centers for Disease Control and Prevention, Atlanta GA ; Paul A. Offit, MD, Chief, Division of Infectious Diseases, Director, Vaccine Education Center, The Children's Hospital of Philadelphia; Professor of Pediatrics, Maurice R. Hilleman Professor of Vaccinology, Perelman School of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Kathryn M. Edwards, MD, Sarah H. Sell and Cornelius Vanderbilt Chair in Pediatrics, Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee and Stanley A. Plotkin, MD, Emeritus Professor of Pediatrics, University of Pennsylvania, Emeritus Professor, Wistar Institute, Former Chief, Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA; Former Medical and Scientific Director, Pasteur Merieux Connaught (now Sanofi Pasteur), Marnes-la-Coquette, France
- Cover Image
- Title Page
- Copyright
- Dedication
- Contributors
- Foreword
- Preface to the First Edition
- Preface to the Eighth Edition
- Acknowledgments
- Table of Contents
- Section I General Aspects of Vaccination
- Chapter 1 A Short History of Vaccination
- EARLY DEVELOPMENTS
- FIRST HALF OF THE 20TH CENTURY
- SECOND HALF OF THE 20TH CENTURY
- RECOMBINANT PROTEIN VACCINES
- 21ST CENTURY
- KEY REFERENCES
- REFERENCES
- Chapter 2 Vaccine Immunology
- WHAT ARE THE MAIN EFFECTORS OF VACCINE RESPONSES?
- HOW DO VACCINES MEDIATE PROTECTION?
- FROM INNATE TO ADAPTIVE IMMUNITY ACTIVATION: THE FIRST STEPS AFTER IMMUNIZATION
- VACCINE ANTIBODY RESPONSES
- KEY REFERENCES
- REFERENCES
- Chapter 3 Non-specific Effects of Vaccines
- INTRODUCTION
- EVIDENCE FROM CLINICAL STUDIES
- GENERAL CONSIDERATIONS
- IMMUNOLOGICAL AND MOLECULAR MECHANISMS
- FUTURE PERSPECTIVES
- KEY REFERENCES
- REFERENCES
- Chapter 4 Correlates of Protection
- PRINCIPLES OF PROTECTION
- STATISTICAL ISSUES IN DEVELOPING IMMUNE CORRELATES OF PROTECTION
- COMPLEXITY OF CORRELATES
- CONCLUSIONS
- KEY REFERENCES
- REFERENCES
- Chapter 5 The Vaccine Industry
- VACCINE DEVELOPMENT
- ROLE OF PARTNERS
- RESPONSE TO COVID-19 PANDEMIC
- FUNDING SOURCES FOR VACCINE RESEARCH AND DEVELOPMENT
- PRICING OF VACCINES
- ACKNOWLEDGMENTS
- REFERENCES
- Chapter 6 Vaccine Manufacturing
- MANUFACTURING BASICS
- EXAMPLES OF VACCINE PRODUCTION
- PRODUCT DEVELOPMENT
- INDUSTRY’S RESPONSE TO NEW CHALLENGES
- REFERENCES
- Chapter 7 Evolution of Adjuvants Across the Centuries
- CHANCE AND NECESSITY: THE DISCOVERY OF ADJUVANTS
- A TURNING POINT: BETTER UNDERSTANDING OF IMMUNOLOGY AND ITS IMPACT ON THE DEVELOPMENT OF ADJUVANTS
- DEFINING ADJUVANTS: CLASSIFICATION AND EVALUATION
- THE CASE OF COVID 19
- FUTURE DIRECTIONS
- ACKNOWLEDGMENT
- REFERENCES
- Chapter 8 Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States
- VACCINE ADDITIVES
- MANUFACTURING RESIDUALS
- SENSITIZING SUBSTANCES
- SUMMARY
- REFERENCES
- Chapter 9 Passive Immunization
- MATERNAL ANTIBODIES: THE ORIGINAL PASSIVE IMMUNOTHERAPY
- CRITICAL PARAMETERS FOR PASSIVE IMMUNOTHERAPY
- PASSIVE IMMUNITY TO SMALLPOX AND HEMORRHAGIC FEVER VIRUSES
- PASSIVE IMMUNITY AGAINST RESPIRATORY AND ENTERIC PATHOGENS
- PASSIVE IMMUNIZATION: A PARADIGM SHIFT IN PROGRESS?
- FUTURE OF PASSIVE IMMUNIZATION
- KEY REFERENCES
- REFERENCES
- Section II Licenced Vaccines and Vaccines in Development
- Chapter 10 General Immunization Practices
- VACCINE STORAGE AND HANDLING
- VACCINE ADMINISTRATION
- ALLEVIATION OF PAIN AND DISCOMFORT ASSOCIATED WITH VACCINATION
- AGES FOR ADMINISTRATION OF IMMUNOBIOLOGICS
- SPACING OF VACCINE DOSES
- SIMULTANEOUS ADMINISTRATION OF DIFFERENT VACCINES
- INTERFERENCE BY IMMUNOGLOBULINS
- RECOMMENDATIONS FOR SPACING ADMINISTRATION OF VACCINES AND IMMUNOGLOBULINS
- INTERCHANGEABILITY OF VACCINES FROM DIFFERENT MANUFACTURERS
- HYPERSENSITIVITY TO VACCINE COMPONENTS
- VACCINE COMPONENTS CAUSING HYPERSENSITIVITY
- MANAGEMENT OF ACUTE VACCINE ADVERSE REACTIONS
- SPECIAL CONSIDERATIONS
- BREASTFEEDING AND IMMUNIZATION
- VACCINATION DURING PREGNANCY
- VACCINATION OF HOUSEHOLD CONTACTS
- VACCINES RECEIVED OUTSIDE THE UNITED STATES
- VACCINATION OF PERSONS WITH A PERSONAL OR FAMILY HISTORY OF SEIZURES
- VACCINATION DURING ACUTE ILLNESS
- CONTRAINDICATIONS TO AND PRECAUTIONS REGARDING VACCINATION
- KEY REFERENCES
- REFERENCES
- Chapter 11 Human Adenovirus Vaccines
- HISTORY OF DISEASE
- WHY THE DISEASE IS IMPORTANT
- BACKGROUND
- EPIDEMIOLOGY
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- DOSAGE AND ROUTE: INTRAMUSCULAR, SUBCUTANEOUS, AND ORAL
- IMMUNOGENICITY OF VACCINE
- EFFICACY AND EFFECTIVENESS OF VACCINE
- INDICATIONS FOR VACCINE—WHO AND WHY
- CONTRAINDICATIONS AND PRECAUTIONS
- PUBLIC HEALTH CONSIDERATIONS
- FUTURE VACCINES
- KEY REFERENCES
- REFERENCES
- Chapter 12 Anthrax Vaccines
- BACKGROUND
- EPIDEMIOLOGY
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- PUBLIC HEALTH CONSIDERATIONS
- FUTURE VACCINES
- KEY REFERENCES
- REFERENCES
- Chapter 13 Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)
- BIODEFENSE AND SPECIAL PATHOGEN VACCINES
- VACCINES AGAINST VIRAL DISEASES
- LIMITED-USE VACCINES AGAINST BACTERIAL DISEASES
- PART 2: COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI)
- FUTURE ASPECTS ON VACCINE DEVELOPMENTS FOR BIODEFENCE AND EMERGING INFECTIONS
- REFERENCES
- Chapter 14 Cancer Vaccines
- INTRODUCTION
- GENERAL CONCEPTS OF CANCER VACCINES
- THERAPEUTIC CANCER VACCINE TYPES
- CONCLUSIONS AND FUTURE DIRECTIONS
- REFERENCES
- Chapter 15 Cholera Vaccines
- HISTORY OF DISEASE
- WHY THE DISEASE IS IMPORTANT
- CLINICAL DESCRIPTION AND COMPLICATIONS
- BACTERIOLOGY
- PATHOGENESIS AS IT RELATES TO PREVENTION
- MODES OF TRANSMISSION
- DIAGNOSIS
- CASE MANAGEMENT
- EPIDEMIOLOGY
- IMMUNITY AND IMMUNE MECHANISMS
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- PUBLIC HEALTH CONSIDERATIONS
- FUTURE VACCINES
- ACKNOWLEDGMENT
- KEY REFERENCES
- REFERENCES
- Chapter 16 Combination Vaccines
- TERMINOLOGY
- PRINCIPLES OF COMBINED VACCINES
- COMBINATIONS BASED ON DTWP (OR ITS COMPONENTS)
- COMBINATIONS BASED ON ACELLULAR PERTUSSIS VACCINE
- COMBINATIONS BASED ON HEPATITIS VACCINE, WITHOUT DTP OR DTAP
- COMBINATIONS BASED ON MMR VACCINE
- COMBINATIONS INCORPORATING MENINGOCOCCAL OR PNEUMOCOCCAL CONJUGATE VACCINES
- FUTURE COMBINATION VACCINES
- PRACTICAL ISSUES IN THE USE OF COMBINATION VACCINES
- PUBLIC HEALTH CONSIDERATIONS
- KEY REFERENCES
- REFERENCES
- Chapter 17 Coronavirus Vaccines
- INTRODUCTION: CORONAVIRUSES IN GENERAL
- COVID-19
- VACCINE STRATEGIES FOR COVS OF DOMESTIC AND COMPANION ANIMALS
- IMMUNE RESPONSES ELICITED BY COV
- DEVELOPMENT OF VACCINES FOR SARS-COV AND MERS-COV
- SARS-COV-2 VACCINE DEVELOPMENT
- WANING OF THE IMMUNE RESPONSE AND BOOSTER
- OUTSTANDING ISSUES IN COVID-19 VACCINE DEVELOPMENT
- FUTURE GOALS
- ACKNOWLEDGMENTS
- REFERENCES
- Chapter 18 Cytomegalovirus Vaccines
- CORRELATES OF CYTOMEGALOVIRUS IMMUNITY: IMPLICATIONS FOR VACCINE DESIGN
- VACCINES IN CLINICAL TRIALS
- SUBUNIT VACCINES
- VECTORED VACCINES
- VACCINES IN PRE-CLINICAL DEVELOPMENT
- SUMMARY AND FUTURE PERSPECTIVE
- KEY REFERENCES
- REFERENCES
- Chapter 19 Dengue Vaccines
- INTRODUCTION
- DISEASE, VIRUS, EPIDEMIOLOGY, AND PATHOGENESIS
- ACTIVE IMMUNIZATION
- IMMUNOGENICITY OF VACCINE
- EFFICACY AND EFFECTIVENESS
- EXCRETION OF VACCINE VIRUS, IF ANY
- DURATION OF IMMUNITY AND PROTECTION, INCLUDING DESCRIPTION OF REINFECTION IF ANY
- DENGUE HUMAN INFECTION MODEL (DHIM)
- SAFETY (ADVERSE EVENTS)
- INDICATIONS FOR VACCINE—WHO AND WHY
- CONTRAINDICATIONS AND PRECAUTIONS
- PUBLIC HEALTH CONSIDERATIONS
- FUTURE VACCINES (BRIEF)
- KEY REFERENCES
- REFERENCES
- Chapter 20 Vaccines Against Diarrhea Caused by Noncholera Bacteria
- MECHANISMS OF DISEASE AND IMMUNITY
- MUCOSAL VERSUS PARENTERAL VACCINATION
- SPECIFIC VACCINES
- PUBLIC HEALTH PERSPECTIVES, INDICATIONS, AND CHALLENGES FOR VACCINATION
- ACKNOWLEDGMENTS
- KEY REFERENCES
- REFERENCES
- Chapter 21 Diphtheria Toxoid
- INTRODUCTION
- BACKGROUND
- EPIDEMIOLOGY
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- IMMUNOGENICITY OF VACCINE
- EFFICACY AND EFFECTIVENESS OF VACCINE
- DURATION OF IMMUNITY AND PROTECTION
- POSTEXPOSURE PROPHYLAXIS AND THERAPEUTIC VACCINATION
- SAFETY
- INDICATIONS FOR VACCINE—WHO AND WHY
- CONTRAINDICATIONS AND PRECAUTIONS
- PUBLIC HEALTH CONSIDERATIONS
- FUTURE VACCINES
- KEY REFERENCES
- REFERENCES
- Chapter 22 Ebola Vaccines
- INTRODUCTION
- BACKGROUND
- EPIDEMIOLOGY
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- VACCINES IN CLINICAL USE OR ADVANCED CLINICAL DEVELOPMENT
- VACCINE EFFICACY
- PUBLIC HEALTH CONSIDERATIONS
- ACKNOWLEDGMENT
- REFERENCES
- Chapter 23 Nonpolio Enteroviruses
- HISTORY OF DISEASE
- CLINICAL DESCRIPTION
- VIROLOGY
- EPIDEMIOLOGY
- SIGNIFICANCE AS A PUBLIC HEALTH BURDEN
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- HISTORY OF ENTEROVIRUS D68 VACCINE DEVELOPMENT
- KEY REFERENCES
- REFERENCES
- Chapter 24 Epstein–Barr Virus Vaccines
- CONSIDERATIONS FOR DEVELOPING PROPHYLACTIC EBV VACCINES
- PROPHYLACTIC EBV VACCINES TESTED IN CLINICAL TRIALS
- PROPHYLACTIC EBV VACCINES UNDER DEVELOPMENT
- THERAPEUTIC EBV VACCINES UNDER DEVELOPMENT
- SUGGESTIONS FOR FUTURE DEVELOPMENT OF EBV VACCINES
- BARRIERS TO EBV VACCINE DEVELOPMENT
- CONCLUSIONS
- ACKNOWLEDGMENTS
- REFERENCES
- Chapter 25 Haemophilus influenzae Type b Vaccines
- INTRODUCTION
- HISTORY
- BACKGROUND (BOX 25.1)
- EPIDEMIOLOGY (BOX 25.2)
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION (BOX 25.3)
- POLYSACCHARIDE VACCINE
- CONJUGATE VACCINES
- POSTVACCINE ERA: PUBLIC HEALTH CONSIDERATIONS
- FUTURE VACCINES
- CONCLUSION (BOX 25.4)
- KEY REFERENCES
- REFERENCES
- Chapter 26 Hepatitis A Vaccines
- INTRODUCTION
- BACKGROUND
- EPIDEMIOLOGY
- MODES OF TRANSMISSION AND OUTBREAKS
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- VACCINE COVERAGE
- PUBLIC HEALTH CONSIDERATIONS
- THE GOAL OF THE ELIMINATION OF HEPATITIS A
- KEY REFERENCES
- REFERENCES
- Chapter 27 Hepatitis B Vaccines
- BACKGROUND
- BURDEN AND EPIDEMIOLOGY
- PREVENTION OF HEPATITIS B VIRUS
- RESULTS OF VACCINATION
- RECOMMENDATIONS FOR HEPATITIS B VACCINATION
- POSTEXPOSURE PROPHYLAXIS TO PREVENT HEPATITIS B VIRUS INFECTION
- PREVACCINATION AND POSTVACCINATION SEROLOGIC TESTING
- REVACCINATION OF THOSE WHO DO NOT SEROCONVERT
- SUMMARY
- KEY REFERENCES
- REFERENCES
- Chapter 28 Hepatitis C Vaccines
- VIROLOGY
- HEPATITIS C VIRUS INFECTION
- EPIDEMIOLOGY
- IMMUNE RESPONSE TO HEPATITIS C VIRUS
- PROTECTIVE IMMUNITY AGAINST HEPATITIS C VIRUS
- STRATEGIES FOR A HEPATITIS C VIRUS VACCINE
- FUTURE DIRECTIONS
- REFERENCES
- Chapter 29 Hepatitis E Vaccines
- CLINICAL DESCRIPTION
- VIROLOGY AND PATHOGENESIS
- DIAGNOSIS
- TREATMENT
- EPIDEMIOLOGY
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- PRECLINICAL TRIALS: SAFETY, IMMUNOGENICITY, AND EFFICACY
- CLINICAL TRIALS: SAFETY, IMMUNOGENICITY, AND EFFICACY
- PROSPECTS FOR THE FUTURE
- REFERENCES
- Chapter 30 Herpes Simplex Virus Vaccines
- BACKGROUND
- EPIDEMIOLOGY
- ACTIVE IMMUNIZATION
- FUTURE VACCINES
- KEY REFERENCES
- REFERENCES
- Chapter 31 Human Immunodeficiency Virus Vaccines
- DISEASE BURDEN AND EPIDEMIOLOGY
- VIROLOGY
- VIRUS VARIABILITY
- VIRUS–CELL INTERACTIONS
- CLINICAL DISEASE
- HIV PREVENTION
- IMMUNE CORRELATES OF PROTECTION
- SUMMARY AND CONCLUSIONS
- ACKNOWLEDGMENTS
- CONFLICT OF INTEREST STATEMENT
- KEY REFERENCES
- REFERENCES
- Chapter 32 Human Papillomavirus Vaccines
- CLINICAL DESCRIPTION
- VIROLOGY
- PATHOGENESIS
- EPIDEMIOLOGY AND TRANSMISSION
- DIAGNOSIS
- PROPHYLACTIC VACCINES
- CURRENT VACCINES
- TRIALS IN ADOLESCENTS
- IMMUNOGENICITY BRIDGING TRIALS
- COADMINISTRATION WITH OTHER VACCINES
- MECHANISM OF PROTECTION
- DURATION OF PROTECTION
- INDICATIONS
- RECOMMENDATIONS
- PRECAUTIONS AND CONTRAINDICATIONS
- CERVICAL CANCER SCREENING AMONG VACCINATED FEMALES
- PUBLIC HEALTH CONSIDERATIONS
- EPIDEMIOLOGIC IMPACT OF VACCINATION
- SECOND-GENERATION PROPHYLACTIC VACCINES
- THERAPEUTIC VACCINES
- WHY THERAPEUTIC HUMAN PAPILLOMAVIRUS VACCINES HAVE HAD MODEST SUCCESS
- KEY REFERENCES
- REFERENCES
- Chapter 33 Inactivated and Recombinant Influenza Vaccines
- HISTORY AND IMPORTANCE
- BACKGROUND
- EPIDEMIOLOGY
- PASSIVE IMMUNIZATION
- ACTIVE IMMUNIZATION
- IMMUNE RESPONSE TO VACCINATION AND CORRELATES OF PROTECTION
- EFFICACY AND EFFECTIVENESS
- CHALLENGES AND OTHER DIRECTIONS FOR INFLUENZA VACCINES
- PUBLIC HEALTH CONSIDERATIONS
- KEY REFERENCES
- REFERENCES
- Chapter 34 Influenza Vaccine—Live
- WHY THE DISEASE IS IMPORTANT
- INFLUENZA
- VIROLOGY
- PATHOGENESIS AS IT RELATES TO PREVENTION
- LIVE ATTENUATED VACCINES
- HISTORY AND DEVELOPMENT OF COLD-ADAPTED (CA) INTRANASAL LIVE ATTENUATED VACCINE
- CHARACTERISTICS AND FORMULATIONS OF LIVE ATTENUATED INFLUENZA VACCINE
- EFFICACY AND EFFECTIVENESS OF LIVE ATTENUATED INFLUENZA VACCINE
- IMMUNE CORRELATES OF PROTECTION FOR LIVE ATTENUATED INFLUENZA VACCINE
- EFFICACY OF LIVE ATTENUATED INFLUENZA VACCINE COMPARED WITH TRIVALENT INACTIVATED INFLUENZA VACCINE
Στείλτε μια ερώτηση για το προϊόν
Molecular Biology of SARS-CoV-2. Opportunities for Antivirus Drug Development, First edition
187,00€ 208,00€
23-28 ημέρες
Flow Cytometry in Hematolymphoid Neoplasms. A Comprehensive and Practical Guide to Diagnosis
141,00€ 153,00€
23-28 ημέρες
Essentials of Microbiology for Postgraduates: General Bacteriology—Volume 1
140,00€ 152,00€
23-28 ημέρες
Infectious Diseases, Microbiology and Virology. A Q&A Approach for Specialist Medical Trainees
60,00€ 65,00€
23-28 ημέρες
Hospital-Acquired Infections in Intensive Care Unit and their Management. The Indian Perspective
